Drug Profile
sNN 0031
Alternative Names: rh PDGF-BB; sNN-0031Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator NeuroNova AB
- Developer Newron Pharmaceuticals
- Class Antiparkinsonians; Nerve growth factors
- Mechanism of Action Neuron stimulants; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 26 Jan 2016 Newron terminates a phase I trial in Parkinson's disease in Sweden (NCT01829867)
- 28 Oct 2015 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Germany (Intracerebral)
- 28 Oct 2015 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Sweden (Intracerebral)